CRISPR Archives

More News! 14 Oct 2022

ChristianaCare spins out new gene-editing company CorriXR Therapeutics

ChristianaCare has spun out its first commercial biotech private start-up company, CorriXR Therapeutics. CorriXR Therapeutics will use CRISPR gene editing technology to develop new, clinically relevant oncologic therapeutics in areas of unmet medical need, starting with squamous cell carcinoma of the lung. Its close relationship with ChristianaCare and the ChristianaCare Gene Editing Institute positions it […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 6 Oct 2022

Growing hub Lithuania ready to welcome biotech sector to EFIB’22

On October 26 and 27 the Lithuanian capital, Vilnius, is hosting the European Forum for Industrial Biotechnology & the Bioeconomy 2022 (EFIB’22). EFIB, one of Europe’s top biotech events, will bring together business leaders, entrepreneurs, scientists, and investors. Executive director of the Lithuanian Biotechnology Association, Agnė Vaitkevičienė, explains the importance of EFIB and the potential […]

October 6, 2022 - 5 minutesmins - By Jim Cornall

More News! 29 Sep 2022

Removing binding sites for an oncogene can slow cancer cell growth, researchers say

Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers from the University of Helsinki have discovered. They have found a mechanism by which an oncogene commonly activated in cancer patients affects the growth rate of cells. In the future, the findings can help in developing new treatments that could […]

September 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 28 Sep 2022

Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies

Scribe Therapeutics has entered into an agreement with Sanofi which will allow Sanofi use of its CRISPR genome editing technologies. Scribe Therapeutics’ custom genome editing and delivery tools called CasX-Editors (XE) based on foundations such as the CasX enzyme will enable genetic modification of natural killer (NK) cell therapies for cancer and will support Sanofi’s […]

September 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 13 Sep 2022

Scope Biosciences and WUR to improve CRISPR-Cas technology with new funds

Wageningen University & Research (WUR), and its spinoff Scope Biosciences, have received a grant of €150,000 ($152,000) from the European Research Council (ERC). The grant is to further research and enhance the diagnostic technology ScopeDx. This is based on CRISPR-Cas technology. Uniquely, this technology is able to quickly and accurately recognize viral or bacterial RNA. […]

September 13, 2022 - 3 minutesmins - By Jim Cornall

CRISPR, CRISPR-Cas9, genome-editing, gene therapy

News and Trends 8 Sep 2022

CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded

Sigma-Aldrich Co LLC, along with genOway, a preclinical research model space company, announced today (September 8) they have a new structure to their 2018 strategic alliance in the CRISPR/Cas9 field. In 2018, science and technology company Merck, of which Sigma-Aldrich is a subsidiary, announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based […]

September 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Aug 2022

Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics

This week it’s another four interview podcast, and the introduction of a new feature. Our guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO […]

August 26, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

Gene therapies for lung cancer identified by international team of scientists

Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered. CRISPR genome-editing is a powerful tool that gives scientists a cheap and easy way to find and alter a specific piece of DNA within a cell – the ‘cut and paste’ of the biological world. […]

August 24, 2022 - 2 minutesmins - By Liza Laws

CRISPR Therapeutics, CRISPR-Cas9, genome editing, biotech

News and Trends 9 Aug 2022

Study says gene editing with CRISPR/Cas9 can lead to cell toxicity and genome instability

CRISPR/Cas9 is a commonly used gene editing technique. CRISPR allows the introduction of a desired DNA sequence into (virtually) any spot of the genome, thus modifying or inactivating a gene. The technique is widely used in biomedical research and some CRISPR-based therapies are in clinical trials for the treatment of human blood disorders, some types […]

August 9, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Aug 2022

Deciphering the molecular mechanisms of severe COVID-19

Researchers from Fujita Health University School of Medicine in Japan have been investigating COVID-19 to lead to therapeutic options against the severe form of the condition. Levels of proinflammatory cytokines are dramatically elevated in severe COVID-19 patients, the molecular mechanisms of which remain unclear. In a recent article in mBio, the researchers elucidated the role […]

August 3, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

SNIPR Biome announces new patent granted for applications targeting E. coli infections

SNIPR Biome has today (August 2) announced that it has been granted a patent for medical applications supporting the company’s lead program – a bacteriophage cocktail targeting E.coli infections. Granted by the US Patent and Trademark Office (USPTO), the patent adds to its intellectual property portfolio that contains more than 20 granted patents in the […]

August 2, 2022 - 2 minutesmins - By Liza Laws

Opinion 16 May 2022

CRISPR Can Help The Switch To Sustainable Cosmetics

The cosmetics industry is looking for greener ingredients as consumers demand more sustainable products. According to Jon Kratochvil at ERS Genomics, which licenses out patents belonging to the gene editing pioneers Emmanuelle Charpentier and Jennifer Doudna, CRISPR-Cas9 could one day meet the demand for alternatives. The global cosmetics industry is worth more than €480B ($500B), […]

May 16, 2022 - 5 minutesmins - By External Contributor

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us